The Kalyani facility manufactures oncological and non oncological active pharmaceutical ingredients (APIs) in separate and fully segregated areas.

The Kalyani facility has been inspected and approved by USFDA, TGA, and EDQM for various APIs.

A number of new DMFs have been filed from Kalyani facility in US and EU. New state of art commercial plants for manufacturing oncology and high potency APIs are under construction to meet future demands.